Philip Hempleman has become a fan of Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Keep Reading →
December 13 - Hedge Funds, News - Comments
Goldman Capital Management Inc has reduced its exposure to Bacterin International Holdings Inc (NYSEMKT:BONE).
Keep Reading →
December 12 - Hedge Funds, News - Comments
Sam Isaly's Orbimed Advisors focuses on healthcare investments, and it has now disclosed a change to its holdings of Response Biomedical Corp.
Keep Reading →
November 12 - Hedge Funds, News - Comments
In the financial blogosphere, there are a lot of analytical tools for Biogen Idec Inc.
Keep Reading →
August 31 - News - Comments
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors.
Keep Reading →
August 27 - Hedge Funds - Comments
Vocera Communications Inc (NYSE:VCRA) was in 14 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 14 - News - Comments
Given Imaging Ltd. (NASDAQ:GIVN) was in 14 hedge funds' portfolio at the end of March. GIVN has seen an increase in enthusiasm from smart money lately.
Keep Reading →
June 13 - News - Comments
If you'd ask most shareholders, hedge funds are seen as slow, old investment vehicles of the past.
Keep Reading →
June 10 - News - Comments
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of March. ACOR has experienced a decrease in hedge fund sentiment lately.
Keep Reading →
June 8 - News - Comments
In the financial world, there are plenty of metrics market participants can use to track publicly traded companies.
Keep Reading →
June 4 - News - Comments
To the average investor, there are dozens of indicators market participants can use to analyze the equity markets.
Keep Reading →
June 3 - News - Comments
In the smart money’s world, Samuel Isaly’s Orbimed Advisors reported a purchase of some 2.1 million shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a 13D filing with the...
Keep Reading →
May 31 - Hedge Funds, News - Comments
Gilead Sciences, Inc. (NASDAQ:GILD) was in 63 hedge funds' portfolio at the end of March. GILD shareholders have witnessed an increase in hedge fund sentiment of late.
Keep Reading →
May 30 - News - Comments
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) was in 22 hedge funds' portfolio at the end of March.
Keep Reading →
May 30 - News - Comments
To most traders, hedge funds are assumed to be worthless, outdated financial tools of years past.
Keep Reading →
May 28 - News - Comments
Amgen, Inc. (NASDAQ:AMGN) was in 36 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
May 28 - News - Comments
Editor's Note: Related Tickers: Baidu.com, Inc. (ADR) (NASDAQ:BIDU), Micron Technology, Inc.
Keep Reading →
April 18 - News - Comments
According to a 13G filed with the SEC, SAC Capital Advisors, a hedge fund managed by billionaire Steve Cohen, owned 2.4 million shares of Infinity Pharmaceuticals Inc.
Keep Reading →
April 17 - Hedge Funds - Comments
In the 21st century investor’s toolkit, there are a multitude of metrics shareholders can use to track the equity markets.
Keep Reading →
April 16 - News - Comments
If you'd ask most investors, hedge funds are perceived as slow, outdated financial tools of the past.
Keep Reading →
April 15 - News - Comments
In the financial world, there are tons of indicators investors can use to monitor publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Keep Reading →
April 15 - News - Comments
Fluidigm Corporation (NASDAQ:FLDM) was in 7 hedge funds' portfolio at the end of the fourth quarter of 2012.
Keep Reading →
April 15 - News - Comments
Is Uroplasty, Inc. (NASDAQ:UPI) an excellent investment now? The smart money is taking an optimistic view.
Keep Reading →
April 12 - News - Comments
Given Imaging Ltd. (NASDAQ:GIVN) was in 9 hedge funds' portfolio at the end of December.
Keep Reading →
April 6 - News - Comments
If you'd ask most traders, hedge funds are perceived as underperforming, outdated investment tools of years past.
Keep Reading →
April 5 - News - Comments
According to a 13G filed with the SEC, Adage Capital Management, a large hedge fund managed by Phil Gross and Robert Atchinson, owns just over 4 million shares of Medivation Inc...
Keep Reading →
April 4 - Hedge Funds - Comments
MAKO Surgical Corp. (NASDAQ:MAKO) was in 13 hedge funds' portfolio at the end of December. MAKO investors should pay attention to a decrease in hedge fund interest lately.
Keep Reading →
April 3 - News - Comments
XenoPort, Inc. (NASDAQ:XNPT) was in 13 hedge funds' portfolio at the end of December.
Keep Reading →
April 3 - News - Comments
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was in 12 hedge funds' portfolio at the end of December.
Keep Reading →
April 3 - News - Comments
Natus Medical Inc (NASDAQ:BABY) was in 15 hedge funds' portfolio at the end of December. BABY investors should pay attention to an increase in hedge fund interest recently.
Keep Reading →
April 2 - News - Comments
If you'd ask most shareholders, hedge funds are seen as slow, outdated financial vehicles of yesteryear.
Keep Reading →
April 2 - News - Comments
Sequenom, Inc. (NASDAQ:SQNM) was in 15 hedge funds' portfolio at the end of December. SQNM shareholders have witnessed an increase in hedge fund sentiment lately.
Keep Reading →
March 29 - News - Comments
In the 21st century investor’s toolkit, there are a multitude of indicators shareholders can use to monitor the equity markets.
Keep Reading →
March 28 - News - Comments
In the financial world, there are many methods shareholders can use to analyze the equity markets.
Keep Reading →
March 27 - News - Comments
At the moment, there are a multitude of metrics market participants can use to monitor publicly traded companies.
Keep Reading →
March 25 - News - Comments
In today’s marketplace, there are many methods shareholders can use to analyze the equity markets. A duo of the most underrated are hedge fund and insider trading interest.
Keep Reading →
March 21 - News - Comments
A member of Abbott Laboratories (NYSE:ABT)’s Board of Directors, William Osborn, recently bought 10,000 shares of stock at prices between $33.80 and $33.90.
Keep Reading →
February 5 - Insider Trading - Comments
Sam Isaly’s Orbimed Advisors is a large health care fund investing in companies at various stages from venture capital to the public markets.
Keep Reading →
January 8 - Hedge Funds - Comments
Billionaire Ken Fisher isn’t only the head of Fisher Asset Management, but also a long-running Forbes columnist whose picks published in that magazine have tended to outperform...
Keep Reading →
November 27 - Hedge Funds - Comments
Bristol Myers Squibb Co.
Keep Reading →
October 15 - Stock Analysis - Comments
Between April and June of this year, Orbimed Advisors sold 18% of its shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX), finishing the second quarter with exactly 2 million shares...
Keep Reading →
October 1 - Hedge Funds - Comments
Orbimed Advisors, managed by Samuel Isaly, is a hedge fund with a focus on the healthcare sector.
Keep Reading →
September 8 - Hedge Funds - Comments
Peter Kolchinsky’s RA Capital Management reported 7.32% passive stake in Endocyte Inc. (ECYT).
Keep Reading →
December 27 - Hedge Funds - Comments
Samuel Isaly reported his amended 13F portfolio on November 23rd. He made a lot of changes to his original third quarter 13F which was filed a few days ago.
Keep Reading →
November 29 - Hedge Funds - Comments
Samuel Isaly’s Orbimed Advisors filed for its recent insider sales in Anthera Pharmaceuticals Inc (ANTH) on November 18th.
Keep Reading →
November 22 - Hedge Funds, Insider Trading - Comments
Regeneron Pharmaceuticals Inc.'s (REGN) shares rose 13.73% in trading on Monday after U.S.
Keep Reading →
November 21 - Hedge Funds, Market Movers - Comments
Shares of Inhibitex (INHX) more than doubled Friday morning.
Keep Reading →
November 4 - Hedge Funds - Comments
Humana Inc (HUM) swelled from $80.24 a share at open on Monday to hit anew 52-week high of $87.32 a share after it "announced earnings of $444.8 million, or $2.67 a share, up ...
Keep Reading →
October 31 - Hedge Funds - Comments
Daniel Gold’s QVT Financial sold 650 thousand shares in Anadys Pharmaceuticals Inc. (ANDS) on October 17th. According to the firm’s Form 4 and amend 13D on October 19th.
Keep Reading →
October 20 - Hedge Funds, Insider Trading - Comments
Edwards Lifesciences Corp (EW) "third-quarter earnings rose 7.5% on a tax benefit as the heart-valve maker's investments in its expected Sapien launch hurt margins, despite sales...
Keep Reading →
October 20 - Hedge Funds - Comments